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This article provides a summary of the findings presented at
a WHO informal consultation on improving influenza
vaccine virus selection held at WHO headquarters, Geneva,
Switzerland, 14–16 June 2010.1
Global Influenza Surveillance network
Since 1952, the WHO Global Influenza Surveillance and
Response System (GISRS) has played a key role in
monitoring the evolution and distribution of influenza
viruses as well as making recommendations on virus strains
to be used in human influenza vaccines. The GISRS also
monitors, provides risk assessments of potential pandemic
viruses and offers guidance on appropriate public health
responses. A number of recent events including the
expanded role of GISRS following the adoption of the
International Health Regulations in 2005, growing aware-
ness of the continued threat posed by H5N1 and reflection
on the 2009 H1N1 pandemic marked a good opportunity to
revisit vaccine virus selection, and in June 2010, a WHO
informal consultation was held in Geneva, Switzerland, to
critically review the process by which vaccine virus strains
are selected.
Vaccine virus selection process
The vaccine virus selection process involves a high level of
coordination and relies on continual integration of virolog-
ical data and epidemiological information from National
Influenza Centres (NICs), antigenic and genetic character-
ization of viruses by WHO Collaborating Centres (WHO-
CCs) and the preparation of suitable reassortants and
reagents for vaccine standardization by Essential Regulatory
Laboratories. Collaboration and coordination between
human and animal influenza networks are also critical to
the vaccine virus selection process in terms of the improved
integration of data on animal and human viruses, the
identification of unusual human influenza A viruses, the
evaluation of pandemic risk and the selection of candidate
viruses for pandemic vaccines.
Global surveillance of influenza activity is a crucial
component to the virus selection process, and through
training workshops, assessments and donation, significant
increases in trained laboratory personnel and equipment
have been realized, with resulting expansion in both
geographical surveillance coverage and in the capacities of
NICs and other laboratories. These gains have led to a
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significant increase in the volume of information reported to
WHO on the spread, intensity and impact of influenza.
Other initiatives such as the WHO Shipment Fund Project
have facilitated the timely sharing of clinical specimens and
virus isolates and contributed to a more comprehensive
understanding of the global distribution and temporal
circulation of different viruses.
Improving the vaccine virus selection
process
Advances in molecular diagnosis and the accumulation of
genetic sequence data have aided in ensuring the optimal
effectiveness of vaccines. However, there remain a number of
challenging constraints including variations in the various
assays, the possibility of complications resulting from non-
antigenic changes, the limited availability of suitable vaccine
viruses and the requirement for recommendations to be
made up to a year in advance of vaccine use due to
production constraints.
Despite the availability of newer assay technologies that
may be amenable to automation (e.g. advanced recombi-
nant DNA and protein technologies) and difficulties in
standardizing results across laboratories, the haemaggluti-
nation inhibition (HAI) assay is likely to remain the test of
choice for the antigenic characterization of viruses in the
foreseeable future as it is a simple, rapid and reproducible
surrogate assay for virus neutralization. Other technologies
such as microtitre neuraminidase inhibition assays may also
have an impact on both vaccine virus selection and vaccine
development.
Microneutralization assays based on measuring virus
replication, cell viability or neuraminidase activity are an
important complement to the HAI assay in virus antigenic
characterization. Improvements in the use and potential
automation of such assays should facilitate large-scale
serological studies, while other advanced techniques such
as epitope mapping should allow for a more accurate
assessment of the quality of a protective immune response,
and aid the development of additional criteria for measur-
ing immunity.
Standardized seroepidemiological surveys to assess the
impact of influenza in a population could help to establish
well-characterized banks of age-stratified representative sera
as a national, regional and global resource while providing
direct evidence of the specific benefits of vaccination. Such
surveys would not only strengthen the comparability of
serological data generated at different laboratories but
facilitate the comparison of antibody response to different
viruses.
Technological advances in areas such as high-throughput
genetic sequencing and bioinformatics data collection and
analysis, together with the ongoing accumulation of X-ray
crystallographic data of relevant viral haemagglutin epitopes,
should accelerate understanding of the genetic and pheno-
typic changes that underlie virus evolution and aid in
predicting the influence of amino acid changes on virus
antigenicity.
Complex mathematical modelling techniques are increas-
ingly being used to shed light on the evolution and
epidemiology of influenza viruses. However, without a fuller
understanding of the underlying evolutionary and biological
process involved, their value in predicting the timing and
nature of future antigenic and genetic changes is likely to be
limited. The use of less complex, non-mechanistic statistical
algorithms, such as those already used as in antigenic
cartography, and phylogenetic modelling is more likely to be
useful in aiding vaccine virus selection and assessment of the
pandemic potential of avian and other animal influenza
viruses.
Conclusion
The WHO GISRS and its partners are continually working to
identify improvements, harness new technologies and
strengthen and sustain collaboration. Continued progress
relies on strong surveillance systems and the establishment
and maintenance of cross-cutting collaborations. WHO will
continue in its central role of coordinating worldwide
expertise to meet the increasing need for influenza vaccines
and will identify and support efforts to improve the vaccine
virus selection process, including periodic review of the
vaccine virus selection process via international consultations.
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